Slides
Page 1
Private & Confidential Investor Presentation August 03, 2026
Page 2
2 Private & Confidential Disclaimer This presentation has been prepared by Krishna Institute of Medical Sciences Limited (the “Company”) solely for informational purposes. It should not be construed as an offer, solicitation, or recommendation to purchase or subscribe for any securities of the Company or its affiliates. The information contained herein has been compiled from sources believed to be reliable; however, the Company makes no representation or warranty, express or implied, as to the accuracy, completeness, or correctness of such information. Recipients are advised not to place undue reliance on this presentation and are encouraged to conduct their own independent analysis and consult with professional advisors before making any investment or business decisions. This presentation may contain forward-looking statements that involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance, or achievements of the Company to differ materially from those expressed or implied. These statements reflect the current expectations and beliefs of the Company’s management as of the date hereof and are subject to change without notice. The Company undertakes no obligation to update or revise any forward-looking statements in light of new information or future events. Neither the Company nor any of its directors, officers, employees, affiliates, or advisors accepts any liability whatsoever for any loss, cost, or damage arising directly or indirectly from the use of this presentation or its contents. This presentation has not been approved and will not be reviewed or approved by any statutory or regulatory authority in India or by any stock exchange(s) in India. This material does not purport to be comprehensive or to contain all the information a potential investor may require. Any investment decision should be based on a thorough review of publicly available information and independent professional advice suited to the specific circumstances of each investor. By accessing or attending this presentation, you acknowledge that you understand and agree to the terms of this disclaimer. Any disputes arising from or relating to this presentation shall be governed by and construed in accordance with the laws of India, and the courts in Hyderabad, Telangana, India shall have exclusive jurisdiction.
Page 3
3 Private & Confidential Most Preferred Healthcare Provider PATIENTS DOCTORS EMPLOYEES INVESTORS Affordable Quality Care Best-in-Class Facilities Patient Centric Systems & Processes Clinical Outcome Driven Excellence Latest Medical Technology Strong Academics & Research Oriented Enriching Atmosphere Collaborative Culture Growth Driven Career Approach Transparent Governance Strong Operational Performance Consistent Growth VISION: To be the most preferred healthcare services brand by providing affordable care and best clinical outcomes to patients. And to be the best place to work for doctors and employees. OUR MISSION: Provide affordable quality care to our patients with patient-centric systems and processes. Enable clinical outcome-driven excellence by engaging modern medical technology. Provide a strong impetus for doctors to pursue academics and medical research. Driven by a Vision
Page 4
4 Private & Confidential Brain • Neurology • Neurosurgery • Psychiatry • Neuro Rehabilitation Heart • Cardiology • Cardiac Surgery • Vascular Surgery • Heart Transplant • Cardio Rehabilitation Lung • Pulmonology • Interventional Pulmonology • Thoracic surgery • Lung Transplant ENT • Ear • Nose • Throat • Head and Neck Surgery Eyes • Ophthalmology Gastro Intestinal Tract • Medical Gastroenterology • Surgical Gastroenterology • Hepatobiliary Pancreatic Surgery • Liver Transplant • Bariatric Surgery Genito Urinary Tract • Nephrology • Urology • Andrology • Renal Transplant • Gynecology • Urogynecology • IVF and ART • Fetal Medicine • Obstetrics Oncology • Medical Surgical and Radiation • BMT and Hematology Bones and Spine • Orthopedics • Arthroscopic Surgery • Spine Surgery • Ortho Rehabilitation Skin • Dermatology • Cosmetology • Plastic and Reconstructive Surgery Orthodontics • Maxillo Facial Surgery Anaesthesia • OT Anaesthesia • Day care Anaesthesia • Pain Medicine General Specialities • Internal Medicine • General Surgery • Diabetology & Endocrinology Pediatrics • Pediatrics & Pediatric Sub Specialities • Neonatology Radiology • Imaging • Interventional Radiology Lab Services • Pathology • Microbiology • Biochemistry • Molecular Biology • Clinical Hematology Critical Care Services • ICU • CTICU • SICU • NICU • PICU • Neuro ICU • ECMO ICU • Post Transplant ICU Hospital Infection Control • Clinical Infectious Diseases Multi Specialty Care
Page 5
5 Private & Confidential A legend in CT Surgery, Dr. Bhaskara Rao Bollineni {MBBS, MS, DNB (CT Surgery)} is one of the very few Cardio-Thoracic Surgeons in the country, who performed over 30000 surgeries in his career spanning over more than 25 years. Well known in the medical fraternity for his passion towards his profession, Dr. Bhaskara Rao Bollineni started his entrepreneurial journey at “Mahavir Cardio Vascular Centre” in Hyderabad with 50 beds and performed heart surgeries at an unimaginable low cost of just Rs. 45,000 only. Dr. Bhaskara Rao Bollineni never turned away any patient from the hospital for want of money. The brand “Krishna Institute of Medical Sciences”, under Dr. Bhaskara Rao Bollineni aegis began its journey in 2004 with a 300 bed hospital on par with the then established hospitals of Hyderabad in professional excellence, the state of art technology and infrastructure facilities. Today KIMS is spread across Telangana, Andhra Pradesh, Maharashtra, Karnataka and Kerala. Dr. Bhaskara Rao Bollineni was instrumental in formulating Rajiv Gandhi Aarogyasri scheme, first time launched in Andhra Pradesh in 2007 for providing health care to the poorest of the poor. This prestigious scheme has won him accolades from all quarters of the country and the world. He was the chief architect of Aarogyashri scheme for both creating it and implementing it successfully. This well formulated scheme has become so popular that the other States in India have emulated it time and again. Dr. Bhaskara Rao Bollineni - Visionary Behind KIMS Chairman & Managing Director
Page 6
6 Private & Confidential Dr. Abhinay Bollineni Executive Director & CEO Dr. Abhinay Bollineni joined KIMS Hospitals in 2013 and spent the next couple of years in Hospital Operations before taking charge of Strategy & Marketing for the Group in 2015. He was appointed as the CEO in 2019. Dr. Abhinay Bollineni completed MBBS from the Deccan Medical College, Hyderabad, in 2010. He was the lone qualified medical practitioner from India to be selected by the office of Hillary Clinton in 2011, where he participated in the ‘International Visitor Leadership Program on Oncology: Research, Prevention and Treatment’ held by the US Department of State He was named in Business World’s “BW 40 Under 40” list in 2019. Under his stewardship, KIMS Hospitals got successfully listed on the Stock Exchanges in India in 2021. Dr. Abhinay Bollineni is passionate about using technology to enhance patient experience and clinical care. Towards this, he has spearheaded vital initiatives such as Financial counseling tool which uses AI to help patients with surgery costings among many others
Page 7
7 Private & Confidential Board of Directors Dr. Bhaskara Rao Bollineni Chairman & Managing Director Dr. Abhinay Bollineni Executive Director & CEO Mrs. Anitha Dandamudi Whole-time Director Mr. Saumen Chakraborty Independent Director, Chairman (Audit Committee) Mr. Ratna Kishore Kaza Independent Director Chairman (Nomination & Remuneration Committee) Mr. Venkata Ramudu Jasthi Independent Director Mr. Adwik Bollineni Executive Director Mrs. Y . Prameela Rani Independent Director Chairman (Stakeholders’ Relationship Committee) Mr. Suresh Natwarlal Patel Independent Director
Page 8
8 Private & Confidential Shareholding Pattern - As on 30th June, 2026 Promoters, 32.5% DII, 34.5% Retail Pre IPO, 6.5% Retail & Others, 9.1% FII, 17.4% Share Holder Share Holding % SBI MF 4.8% Axis MF 4.4% HDFC MF 4.0% Invesco MF 3.5% Kotak Fund 3.0% Amansa Holdings Private Limited 2.2% LILAC Investments Limited 1.9% SBI Insurance 1.7% Nippon MF 1.7% Nomura 1.5% Top Institutional Share Holders
Page 9
9 Private & Confidential Modern Medical Technology Other Key Equipments • O-Arm Scanner • Spy Glass • Fibroscan • Novalis Tx Linear Accelerator • Cuvis Ortho Robo • EBUS • STEALTH STATION S8 • IMPELLA • EVIS X1 Endoscopy System • 4-Arm HD da Vinci Robotic Surgical System 4-Arm HD da Vinci Robotic Surgical System Facilitates complex surgeries that are virtually scarless. New Robots procured for Secunderabad, Kondapur, Nagpur & Kannur. MrGFUS Focussed Ultrasound Revolutionary Knifeless Brain procedure for treating tremors. Proven to reduce Tremors severity and improve quality of life for Parkinson’s & Essential Tremors Patients. Mako Robotic for Knee Replacement Produces minimal blood loss and a smaller scar. Helps preserve healthy bone and soft tissue. Results in less post-operative pain than manual techniques. ESWL Dornier It offers powerful imaging, maximized energy, and enhanced efficiency. It allows for better diagnosis, better treatment, and better patient follow-up at no additional radiation risk. Tulsa-Pro System A non- invasive procedure that uses real-time MRI guidance to precisely deliver thermal ablation for treating BPH (Benign Prostatic Hyperplasia) and prostate cancer, preserving surrounding healthy tissue. Gamma Knife A non-invasive radiosurgery procedure that uses focused beams of gamma radiation with real-time imaging to precisely treat brain tumors, vascular malformations, and functional brain disorders - without a surgical incision.
Page 10
10 Private & Confidential Many Firsts... • First in Asia to do Trans catheter Tricuspid Valve replacement procedure done in 2018 • Largest Joint replacement program in South Asia. • One of the largest neuroscience programs for epilepsy among private hospitals in the country • Largest ECMO program (18 machines) in the country. • First hospital in Hyderabad to use an ECMO machine in 2013. • First hospital in Hyderabad to do a Neonatal ECMO • First in India to do TOF repair using CorMatrix patch for pulmonary valve reconstruction in 2017 • First in the country to do Robotic spleen preserving distal pancreatectomy • India’s first COVID Double Lung transplant done in 2020 • India’s first Breathing Lung transplant done in 2021 • First hospital in South India to introduce Da Vinci Robotic System • The first hospital in Andhra Pradesh and Telangana to have been Green OT certified in 2016 • First hospital in India to perform Arch Repair in Neonates and infants without TCA • First Hospital in South India to do Total Skin Electron Beam Radiation therapy in 2018 • Number 1 player in Organ transplantation speciality (Heart, Lung, Liver and Kidney)* • Number 1 in Nephrology treatments in Andhra Pradesh* • Number 1 in Neurosurgery & Poly trauma treatments in Andhra Pradesh* • Number 1 in Cardio related surgeries and treatments programs in Andhra Pradesh * • Number 1 in Urology (Genito-Urinary) surgeries performed in Andhra Pradesh*
Page 11
11 Private & Confidential Key Accomplishments Neurology India Journal 2016 Neurology Department at KIMS Secunderabad ranked 3rd in India National Quality Excellence Awards 2019 KIMS Sec. Best Super-Specialty Hospital in Telangana Times Health Survey Times of India 2021 Ranked No.1 in Hyderabad for Cardiology, Neurosciences, Nephrology, Emergency & Trauma 2020 Only Hospital in Telangana to get NABH Accredition for Emergency Department Pharmacie De Qualite (PDQ) Certification Overall PDQ Evaluation Performance Score - 98% Grading - PLATINUM Ranked No. 1 Hospital by Times of India, Hyderabad ‘Patient Friendly Hospital’ AHPI Health Care Excellence Award (2017) NABH Digital Standards Accreditation received for Kondapur INTERNATIONAL ACCREDITATION QUALITY & PATIENT SAFETY American Accreditation Commission International (AACI) Accredited 2nd Best Hospital in Hyderabad (2021 & 2022) ‘Best Hospital to Work For’ AHPI Global Conclave Award (2019) National Quality Excellence Awards 2019 for Best Super Specialty Hospital in Telangana
Page 12
12 Private & Confidential Consistent Performer over 2 decades (Rupees in Millions) 1) *EBITDA before IND AS and other income 2) **FY22 EBITDA includes share of profit from JV (Sunshine) *EBITDA 2005 2010 2015 2020 2022** 2023 2024 42 317 773 5,766 6,200 2,412 5,217 CAGR: 28.1% 2025 7,590 2026 7,584 Total Revenue 2005 No. of Hospitals: 1 2010 No. of Hospitals: 3 2015 No. of Hospitals: 5 2020 No. of Hospitals: 9 2022 No. of Hospitals: 12 2023 No. of Hospitals: 12 263 1,311 4,280 11,287 16,711 22,235 2024 No. of Hospitals: 12 25,143 CAGR: 26.9% 2025 No. of Hospitals: 18 30,670 2026 No. of Hospitals: 26 39,308
Page 13
13 Private & Confidential KIMS Journey: From Regional Leader to National Healthcare Roadmap Overall Bed Capacity of 9600+ Beds 3,264 2,859 1,309 1,068 800 300Total Kurnool - 200 Gachibowli - 223 Nellore - 2502000 Andhra Pradesh Telangana Maharashtra Kerala Karnataka Tamil NaduYear Rajahmundry - 1952001 Secunderabad - 10002004 Srikakulam - 3002011 Kondapur - 2202014 Ongole - 3502017 Vizag - 4342018 Anantapur - 2502019 Begumpet - 369 Nagpur - 3342022 Vizag II - 335 Asian Transcare - 60 Nashik - 325 Kannur - 1892024 Sangli (O&M) - 350Guntur Shikara (O&M) - 2002025 Thane - 300 Kollam - 320 Thrissur (O&M) - 351 Mahadevapura - 450 Guntur Chakra (O&M) - 100 Kondapur II - 787 Palakkad - 208 Electronic City - 350 Planned Chennai - 300 Kompally (O&M) - 2002026 Rajahmundry II - 350 Anantapur II - 250 Ongole - 50
Page 14
14 Private & Confidential KIMS Journey: Strategic Levers for Future Growth Consistent Growth over 2 decades Achieved 26%+ CAGR in Revenue and 28%+ CAGR in EBITDA, reflecting sustained operational excellence and strategic expansion. Delivering high-quality care through affordable healthcare models, advanced transplant programs, and cutting-edge medical technology. Recent Acquisition: Successfully turned around EBITDA from single-digit % to double-digit % post-integration, reflecting operational and financial improvement. Strategic Doctor Partnerships: Building long-term alignment through equity participation, fostering ownership, retention, and clinical excellence. Regional Market Leadership Strategy: Focused expansion to establish dominant presence in target geographies and accelerate new business growth. Demonstrated Investor Value Creation: Delivered consistent stock performance since listing, reflecting strong fundamentals and strategic growth. Sustained Performance Driving for Long Term Growth These Strategic levers underpin the next phase of expansion Adding 1300+ Beds through Green Field, Acquisitions & O&M Opportunities
Page 15
15 Private & Confidential Q1 FY27 Updates
Page 16
16 Private & Confidential Financial & Operational Highlights - 1/2 Particulars Financial Highlights Q1 FY27 Q4 FY26 Q1 FY26 QoQ (%) YoY (%) FY26 FY25 YoY (%) Operating Revenue 11,795 10,746 8,716 9.8% 35.3% 39,046 30,351 28.6% Other Income 164 97 71 69.1% 131.0% 262 319 -17.9% Total Revenue 11,959 10,843 8,787 10.3% 36.1% 39,308 30,670 28.2% EBITDA 2,398 2,162 1,997 10.9% 20.1% 8,282 8,148 1.6% EBITDA (%) on Total Revenue 20.1% 19.9% 22.7% 21.1% 26.6% PBT* 566 548 1,137 3.3% (50.2%) 3,339 5,581 (40.2%) PBT (%) on Total Revenue 4.7% 5.1% 12.9% 8.5% 18.2% PAT* 374 331 850 13.0% (56.0%) 2,420 4,148 (41.7%) PAT (%) on Total Revenue 3.1% 3.1% 9.7% 6.2% 13.5% Basic EPS(Rs.) 1.04 1.06 1.96 (2.3%) (47.2%) 6.03 9.61 (37.3%) Diluted EPS (Rs.) 1.04 1.06 1.96 (2.3%) (47.2%) 6.03 9.61 (37.3%) IND AS 116 177 195 59 436 239 EBITDA Pre IND AS 2,221 1,967 1,938 12.9% 14.6% 7,846 7,909 (0.8%) (Rupees in Millions) *PBT and PAT includes Statutory impact of new Labour Codes 74 Mn in Q4 FY 26 *PBT and PAT includes (Loss)/gain on fair valuation of Call option (net) 35 Mn In Q4 FY 26 *PBT and PAT includes share of profit from associates 26 Mn in Q4FY26 and 10 Mn in Q1FY27
Page 17
17 Private & Confidential Financial & Operational Highlights - 2/2 Particulars Operational Highlights Q1 FY27 Q4 FY26 Q1 FY26 QoQ (%) YoY (%) IP Volume 72,493 63,595 57,275 14.0% 26.6% OP Volume 6,58,617 6,09,724 5,12,399 8.0% 28.5% ARPOB (Rs) 47,200 47,132 43,011 0.1% 9.7% ARPP (Rs) 1,63,573 1,69,983 1,53,094 (3.8%) 6.8%
Page 18
18 Private & Confidential Group Operating Performance IP VOLUME (‘000) OCCUPIED BEDS / OCCUPANCY %* 51.3% 2,252 Q1 FY26 52.5% 2,548 49.0% 2,761 Q4 FY26 Q1 FY27 50.0% 2,248 FY25 50.5% 2,450 FY26 213 FY25 246 FY26 15.4% 57 Q1 FY26 64 72 Q4 FY26 Q1 FY27 OP VOLUME (‘000) 1,834 FY25 2,300 FY26 25.4% 512 Q1 FY26 610 659 Q4 FY26 Q1 FY27 8.0% *Occupancy (Occupied Beds/Operational Beds) 14.0% ARPOB (‘000) 0.1% 43.0 Q1 FY26 47.1 47.2 Q4 FY26 Q1 FY27 39.2 FY25 44.6 FY26 14.0%
Page 19
19 Private & Confidential Particulars FY 25 FY 26 Q1 FY27 Q4 FY26 Q1 FY26 Bed Capacity# 5,179 6,464 7,459 6,464 5,499 Operational Beds 4,492 4,852 5,639 4,852 4,387 Census Beds 3,924 3,981 4,549 3,981 3,809 Non Census Beds 568 871 1,090 871 578 Occupied Beds 2,248 2,450 2,761 2,548 2,252 Occupancy*** 50.0% 50.5% 49.0% 52.5% 51.3% IP volume 2,13,346 2,46,297 72,493 63,595 57,275 OP volume 18,34,312 23,00,360 6,58,617 6,09,724 5,12,399 ARPOB(Rs.) 39,158 44,644 47,200 47,132 43,011 ARPP(Rs.) 1,43,293 1,59,575 1,63,573 1,69,983 1,53,094 ALOS 3.66 3.57 3.47 3.61 3.56 Total Revenue (Rs.in Mn) 30,670 39,308 11,959 10,843 8,787 EBITDA (Rs.in Mn) 8,148 8,282 2,398 2,162 1,997 EBITDA % to Total Revenue 26.6% 21.1% 20.1% 19.9% 22.7% PBT* (Rs. in Mn) 5,581 3,339 566 548 1,137 PAT* (Rs. in Mn) 4,148 2,420 374 331 850 Group Operating and Financial Performance *PBT and PAT includes Statutory impact of new Labour Codes 74 Mn in Q4 FY 26 *PBT and PAT includes (Loss)/gain on fair valuation of Call option (net) 35 Mn In Q4 FY 26 *PBT and PAT includes share of profit from associates 26 Mn in Q4FY26 and 10 Mn in Q1FY27 ***Occupancy (Occupied Beds/Operational Beds) #787 beds added in Kondapur and 208 beds added in Palakkad in Q1FY27
Page 20
20 Private & Confidential Group Financial Performance (Rupees in Millions) TOTAL REVENUE PBT* 30,670 FY25 39,308 FY26 28.2% 8,787 10,843 11,959 10.3% Q1 FY26 Q4 FY26 Q1 FY27 5,581 FY25 3,339 FY26 1,137 548 566 3.3% Q1 FY26 Q4 FY26 Q1 FY27 (40.2%) EBITDA PAT* 8,148 FY25 8,282 FY26 1.6% 1,997 2,162 2,398 10.9% Q1 FY26 Q4 FY26 Q1 FY27 4,148 FY25 2,420 FY26 (41.7%) 850 331 374 13.0% Q1 FY26 Q4 FY26 Q1 FY27 *PBT and PAT includes Statutory impact of new Labour Codes 74 Mn in Q4 FY 26 *PBT and PAT includes (Loss)/gain on fair valuation of Call option (net) 35 Mn In Q4 FY 26 *PBT and PAT includes share of profit from associates 26 Mn in Q4FY26 and 10 Mn in Q1FY27
Page 21
21 Private & Confidential 1) Intercompany eliminations adjusted in Telangana 2) Telangana - Secunderabad, Kondapur, Gachibowli, Begumpet, MIPPL, Asian Transcare 3) Andhra Pradesh - Nellore, Rajahmundry, Srikakulam, Ongole, Vizag (Sheela Nagar & Seethammadhara), Anantapur and Kurnool 4) *Occupancy (Occupied Beds/Operational Beds) 5) #787 beds added in Kondapur in Q1FY27 Particulars Telangana Andhra Pradesh FY 25 FY 26 Q1 FY27 Q4 FY26 Q1 FY26 FY 25 FY 26 Q1 FY27 Q4 FY26 Q1 FY26 Bed Capacity# 1,797 1,882 2,669 1,882 1,817 2,214 2,314 2,314 2,314 2,214 Operational Beds 1,682 1,694 2,144 1,694 1,702 1,806 1,840 1,909 1,840 1,806 Census Beds 1,394 1,400 1,722 1,400 1,414 1,641 1,634 1,694 1,634 1,641 Non Census Beds 288 294 422 294 288 165 206 215 206 165 Occupied Beds 854 889 881 887 844 1,092 1,009 1,133 1,012 1,023 Occupancy* 50.8% 52.5% 41.1% 52.4% 49.6% 60.5% 54.8% 59.4% 55.0% 56.6% IP volume 91,159 93,038 24,327 22,704 22,876 99,266 1,01,575 28,536 24,735 25,289 OP volume 9,01,117 9,42,195 2,42,274 2,34,498 2,30,258 7,22,487 7,84,509 2,06,906 1,96,525 1,83,536 ARPOB(Rs.) 63,650 69,450 77,009 72,863 69,824 21,130 25,595 25,448 27,178 24,069 ARPP(Rs.) 2,15,676 2,42,340 2,53,856 2,56,277 2,34,464 81,416 92,766 91,940 1,00,106 88,576 ALOS 3.39 3.49 3.30 3.52 3.36 3.85 3.62 3.61 3.68 3.68 Total Revenue (Rs.in Mn) 19,711 22,420 6,235 5,807 5,366 8,108 9,496 2,634 2,500 2,248 EBITDA (Rs.in Mn) 6,062 6,820 1,842 1,765 1,588 1,962 2,337 560 627 498 EBITDA % to Total Revenue 30.8% 30.4% 29.5% 30.4% 29.6% 24.2% 24.6% 21.3% 25.1% 22.2% Operational and Financial Performance - 1/2
Page 22
22 Private & Confidential 1) Maharashtra - Nagpur & Nashik, Thane 2) Kerala - Kannur, Kollam and Palakkad 3) Karnataka - Bengaluru (Mahadevapura and Electronic City) 4) *Occupancy (Occupied Beds/Operational Beds) 5) #208 beds added in Palakkad in Q1FY27 Particulars Maharashtra Kerala Karnataka Group FY 25 FY 26 Q1 FY27 Q4 FY26 Q1 FY26 FY 25 FY 26 Q1 FY27 Q4 FY26 Q1 FY26 FY 26 Q1 FY27 Q4 FY26 FY 25 FY 26 Q1 FY27 Q4 FY26 Q1 FY26 Bed Capacity# 659 959 959 959 959 509 509 717 509 509 800 800 800 5,179 6,464 7,459 6,464 5,499 Operational Beds 630 637 637 637 505 374 401 609 401 374 280 340 280 4,492 4,852 5,639 4,852 4,387 Census Beds 545 442 442 442 410 344 321 481 321 344 184 210 184 3,924 3,981 4,549 3,981 3,809 Non Census Beds 85 195 195 195 95 30 80 128 80 30 96 130 96 568 871 1,090 871 578 Occupied Beds 208 332 373 386 257 94 160 280 187 128 61 94 77 2,248 2,450 2,761 2,548 2,252 Occupancy* 33.0% 52.1% 58.6% 60.6% 50.9% 25.1% 39.9% 46.0% 46.6% 34.2% 21.8% 27.6% 27.5% 50.0% 50.5% 49.0% 52.5% 51.3% IP volume 17,887 29,393 8,731 8,330 5,508 5,034 18,443 7,851 5,367 3,602 3,848 3,048 2,459 2,13,346 2,46,297 72,493 63,595 57,275 OP volume 1,40,401 2,98,296 68,632 84,459 52,082 70,307 2,21,405 96,934 60,305 46,523 53,955 43,871 33,937 18,34,312 23,00,360 6,58,617 6,09,724 5,12,399 ARPOB(Rs.) 32,052 39,402 44,182 39,916 37,016 29,885 29,063 30,125 28,982 29,017 85,320 92,793 93,223 39,158 44,644 47,200 47,132 43,011 ARPP(Rs.) 1,31,299 1,57,484 1,71,610 1,66,264 1,50,231 95,308 91,776 97,781 90,664 93,666 2,62,952 2,60,082 2,61,843 1,43,293 1,59,575 1,63,573 1,69,983 1,53,094 ALOS 4.10 4.00 3.88 4.17 4.06 3.19 3.16 3.25 3.13 3.23 3.08 2.80 2.81 3.66 3.57 3.47 3.61 3.56 Total Revenue (Rs.in Mn) 2,365 4,654 1,504 1,393 832 486 1,713 776 493 341 1,025 810 650 30,670 39,308 11,959 10,843 8,787 EBITDA (Rs.in Mn) 221 (43) 113 69 (65) (97) 78 75 99 (24) (910) (192) (398) 8,148 8,282 2,398 2,162 1,997 EBITDA % to Total Revenue 9.3% (0.9%) 7.5% 5.0% (7.8%) (20.0%) 4.6% 9.7% 20.1% (7.0%) (88.8%) (23.7%) (61.2%) 26.6% 21.1% 20.1% 19.9% 22.7% Operational and Financial Performance - 2/2
Page 23
23 Private & Confidential Ramp-up of Kerala Units (Rupees in Millions) Revenue EBITDA • Expanded clinical capabilities with the launch of Gastro Interventional Radiology, enhancing the hospital’s advanced minimally invasive treatment portfolio. • Demonstrated exceptional multidisciplinary clinical expertise through the successful 111-day management and discharge of a highly complex post-transplant patient, involving graft loss, severe gangrenous groin infections, and recurrent sepsis. • Successfully performed North Malabar’s first Craniosynostosis surgery, reinforcing the institution’s position as a regional leader in advanced and specialized healthcare services. Kannur 322.0 84.3 Q4FY26 253.6 12.4 Q1FY26 353.6 52.7 Q1FY27 EBITDA Positive NABH - Entry level • Advanced clinical capability milestone achieved with the hospital’s first successful Cryobiopsy procedure, strengthening its position in cutting- edge diagnostic and interventional care. • Launched a dedicated Pediatric Intensive Care Unit (PICU), expanding critical care infrastructure and enhancing specialized pediatric healthcare services. • Successfully performed the first Thoracoscopy procedure in Kollam district, underscoring the hospital’s leadership in introducing advanced minimally invasive surgical techniques to the region. Kollam 170.5 87.3 14.8 (35.9) Q4FY26Q1FY26 219.3 14.8 Q1FY27 NABH - In Pipeline EBITDA Positive • Successfully commissioned and operationalized in April 2026. • Established clinical leadership through key procedural firsts, including the hospital’s first IVUS-Guided Coronary Angioplasty in April 2026 and a complex High-Risk Reverse Shoulder Surgery in May 2026. • Strengthened transplant care capabilities by securing the Transplant Licence in May 2026 and successfully completing the hospital’s first Renal Transplant in July 2026, with both donor and recipient discharged safely. • Demonstrated excellence in advanced tertiary care services, reinforcing the hospital’s position as a destination center for complex and specialized clinical interventions. Palakkad 203.1 7.0 Q1FY27 NABH - Accredited EBITDA Positive
Page 24
24 Private & Confidential Ramp-up of Maharashtra Units (Rupees in Millions) • Strengthening Access & Institutional Reach Expanded patient access through successful empanelments with CGHS, ESIC and leading insurance partners • Expanding High-Value Clinical Services Launched the Oxford Partial Knee Replacement Program, adding advanced minimally invasive orthopaedic solutions and strengthening our premium clinical portfolio. Established North Maharashtra’s First Vertigo Testing Facility, addressing a significant regional healthcare gap and expanding specialized diagnostic capabilities. • Driving Clinical Excellence & Volume Growth Achieved a landmark milestone of 50 Joint Replacement Surgeries in a Single Month, reflecting strong patient confidence, growing market demand, and enhanced surgical capabilities. • Transplant Program Expansion: Secured licenses for Heart, Lung, and Kidney Transplant programs, laying the groundwork for advanced multi-organ transplant services and future growth. • Advanced Clinical Technology: Introduced Thane's first Cardiology Laser System and an advanced Orthopedic Robotic Surgery System, reinforcing KIMS Thane's leadership in tertiary and quaternary care. • Expanded Patient Access: Empanelled under GIPSA and MJPJAY , enhancing access for insured and government-scheme beneficiaries. Revenue EBITDA Nashik 218.0 (14.6) Q4FY26 248.8 10.8 Q1FY27 152.5 (97.9) Q1FY26 NABH - Entry level Thane 463.7 (70.9) Q4FY26 482.0 (79.9) Q1FY27 55.8 (92.3) Q1FY26 NABH - Accredited EBITDA Positive
Page 25
25 Private & Confidential Ramp-up of AP & Karnataka Units (Rupees in Millions) Revenue EBITDA Vizag QNRI 214.0 (0.3) Q1FY26 360.4 25.5 Q4FY26 398.8 63.2 Q1FY27 NABH - Accredited • NABH Accreditation secured for KIMS Mahadevapura. • NABL Accreditation Audit successfully completed at Mahadevapura. • Completed 24 organ transplants, including: Renal, Liver, Lung & Heart Transplants • Completed 100+ robotic surgeries, including advanced orthopaedic procedures. • Performed 50+ joint replacement surgeries during the quarter. Mahadevapura (Bengaluru) 485.7 (146.2) Q4FY26 550.6 (15.8) Q1FY27 NABH - Accredited Electronic City (Bengaluru) 164.0 (252.0) Q4FY26 259.0 (176.6) Q1FY27 NABH - In Pipeline EBITDA Positive • Clinical Capability Expansion & Specialty Strengthening Established a comprehensive Oncology Center of Excellence, offering integrated services across Medical Oncology, Surgical Oncology, Radiation Oncology, Nuclear Medicine, Hemato-Oncology, and Bone Marrow Transplantation (BMT). Strengthened tertiary care capabilities through the addition of leading specialists in ENT, Plastic Surgery, Orthopedics, Surgical Gastroenterology, Urology, and Dental Sciences. Launched high-value specialty programs, including Robotic Surgery, Aesthetic Medicine, and IVF Services, enhancing service differentiation and revenue potential. • Infrastructure & Technology Enhancement Completed major infrastructure upgrades, including Operating Theatre modernization, PET-CT installation, and Biplane Cath Lab commissioning, significantly enhancing diagnostic and procedural capabilities. Added specialized care units and premium patient infrastructure, including PICU, NICU, Labor Suites, Premium & Suite Rooms, BMT Suites, and Executive Dialysis Facilities.
Page 26
26 Private & Confidential Ramp-up of O&M Units (Rupees in Millions) Revenue EBITDA Revenue and EBITDA are as per management accounts. • Deeper Market Penetration: Expanded geographic coverage and outreach initiatives have enabled deeper market penetration, enhancing patient access, referral networks, and overall patient channelization. • Growing Consumer Preference: KIMS UAIMS Hospital has witnessed a positive shift in consumer preference, with an increasing number of patients choosing the hospital as their preferred healthcare destination in the region. • Expansion of Academic Programs: The introduction of DNB Anaesthesia and IDCCM programs is progressing well, further strengthening the institution’s academic and clinical excellence ecosystem. Sangli 235.3 13.5 Q1FY26 243.6 14.8 Q4FY26 277.4 22.6 Q1FY27 EBITDA Positive NABH - Entry level • Cash and Insurance-focused model. • Top-tier clinical talent onboarded across Cardiac, Neuro, Gastro, and Mother & Child specialties. • Transplant programs (Liver & Kidney) initiated within 8 months of operations. • Digital-first market approach in Guntur driving strong lead generation and OP growth. • Introduced Guntur’s first IVUS system and C-Plex machine for complex case management. Guntur 195.0 (22.5) Q1FY26 272.3 (1.8) Q4FY26 NABH - Entry Level 317.9 18.7 Q1FY27 EBITDA Positive • GIPSA Empanelment : Successfully secured GIPSA insurance empanelment within the first three months of operations • Strong Cath Lab Performance: Achieved 200+ catheterization laboratory procedures in just three months, reflecting rapid adoption of advanced cardiac care services. • Robust Surgical Volumes: Completed 450+ surgeries within the first four months of operations, showcasing the hospital’s expanding clinical capabilities and patient confidence. Kompally NABH - In Pipeline 121.4 (92.1) Q1FY27
Page 27
27 Private & Confidential Revenue Mix & Cluster Profile (Group Q1FY27) 1) Telangana - Secunderabad, Kondapur, Begumpet, Gachibowli, Asian Transcare & MIPPL 2) Andhra Pradesh - Nellore, Rajahmundry, Srikakulam, Ongole, Vizag (Sheela Nagar & Seethammadhara), Anantapur and Kurnool 3) Maharashtra - Nagpur, Nashik & Thane 4) Kerala - Kannur, Kollam & Palakkad 5) Karnataka - Bengaluru (Mahadevapura and Electronic City) PAYOR MIX Cash 52% Aarogyasri 4% Insurance 32% Corporate 12% CLUSTER EBITDA Andhra Pradesh 23.4% Telangana 76.8% Maharashtra 4.7% Kerala 3.1% Karnataka (8.0%) CLUSTER TOTAL REVENUE Andhra Pradesh 21.9 Telangana 52.2% Maharashtra 12.6% Karnataka 6.8% Kerala 6.5% Oncology 7% Neuro Sciences 11% Orthopaedics 15% Gastric Sciences 9% Organ Transplant 3% Mother & Child 9% Cardiac Sciences 15% Renal Sciences 9% Others 22% SPECIALITY MIX
Page 28
28 Private & Confidential Key Achievements in Q1 FY27
Page 29
29 Private & Confidential Key Achievements in Q1 FY27
Page 30
30 Private & Confidential Corporate Structure (As on 30th June 2026) Krishna Institute of Medical Sciences Limited KIMS Secunderabad (100%) KIMS Nellore (100%) KIMS QNRI Visakhapatnam (100%) KIMS Rajahmundry (100%) KIMS Swastha Kerala (100%) KHPL Rajahmundry (100%) KIMS Ongole (100%) Doctor Partnership Hospitals AHPL Srikakulam (65.9%) KHEPL Kondapur (90.9%) KIMS ICON Visakhapatnam (51.0%) KIMS Saveera Anantapur (74.5%) KIMS Kurnool (55.0%) KIMS Sunshine Begumpet & Gachibowli (76.2%) MIPPL (Meda) Hyderabad (51.0%) KIMS-Manavata Nashik (51.0%) SPANV Nagpur (69.3%) KIMS Hospitals Bengaluru (79.9%) KIMS Thane (100%) Units Wholly Owned Subsidiaries
Page 31
31 Private & Confidential Thank You